Kathleen M. Shuey, MS, RN, AOCN®, APRN, BC, is a nurse manager of education and admixture implementation at U.S. Oncology in Albuquerque, NM. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)

Gail Wilkes, RNC, MS, AOCN®, is an oncology nurse educator at Boston Medical Center in Massachusetts. Wilkes is a member of the speaker’s bureau for Sanofi-Synthelabo, Inc., the manufacturer of oxaliplatin (EloxatinTM). (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Soc...

This feature provides a platform for oncology nurses to illustrate the many ways that leadership may be realized and professional practice may transform cancer care. Possible submissions include but are not limited to overviews of projects, accounts of the application of leadership principles or theories to practice, and interviews with nurse leaders. Descriptions of activities, projects, or ac...

347 Ruth Zu-Kei Lin, RN, MSN, AOCN®, APN-C, is an oncology clinical nurse specialist at Morristown Memorial Hospital (MMH) in New Jersey; Susan Fowler, PhD, RN, CNRN, FAHA, is a clinical nurse researcher at the Visiting Nurse Association of Central Jersey in Red Bank and was a clinical nurse researcher at MMH at the time of this research; and Craig A. Dise, MD, PhD, is chair of pathology and Ra...

Oncology nursing aims to promote physical and psychosocial well-being of individuals and families at risk for, or living with, a life-threatening illness. A basic component of nursing practice is the nurse-patient relationship (Canadian Nurses Association, 2002). This relationship has been shown to have a positive impact on individuals' well-being as they journey through their cancer experience...

A physician/nurse collaborative team sought to determine whether a nurse-led telephone clinic (Teleclinic) could effectively and safely be used to follow patients with indolent and chronic hematological malignancies. Patients seen at their routine follow-up visit were assessed for eligibility for the Teleclinic, then referred to the pilot Teleclinic by their oncologist. Patients were interviewe...